What are the new 'super-jabs' for weight loss?

Super-jabs are next-generation weight-loss drugs that combine multiple hormones to create a stronger, longer-lasting feeling of fullness, potentially leading to greater weight loss.

How do new weight-loss drugs like Eli Lilly's retatrutide compare to Ozempic?

Newer drugs like retatrutide target three hormones, aiming for over 24% body weight loss, while Ozempic targets one hormone and typically achieves around 15% weight loss.

When will new weight-loss drugs like CagriSema be available on the NHS?

Novo Nordisk hopes to submit CagriSema for approval next year, potentially reaching NHS patients as early as 2026.

Home / Health / New Super-Jabs Promise 25% Weight Loss

New Super-Jabs Promise 25% Weight Loss

25 Nov

•

Summary

New weight-loss jabs target multiple hormones for enhanced effectiveness.
These advanced treatments aim for up to 25% body weight loss.
Some new drugs may require only monthly injections, improving convenience.

Next-generation weight-loss medications, dubbed 'super-jabs,' are poised to revolutionize obesity treatment. Unlike earlier drugs focusing on a single hormone like GLP-1, these advanced therapies combine multiple hormones, such as GLP-1, GIP, and glucagon. This multi-pronged approach aims to induce a more profound and sustained sense of fullness, potentially helping individuals who have plateaued with current treatments or see minimal results.

Early clinical trials indicate these new combination drugs could enable patients to shed approximately 25% of their body weight. This represents a significant improvement over existing treatments, which typically yield around 15% weight loss. Furthermore, some of these novel injections, like Metsera's MET-233i, are being developed for once-monthly administration, offering a more convenient regimen compared to the current weekly injections.

Several pharmaceutical giants are heavily invested in this burgeoning field, with companies like Eli Lilly and Novo Nordisk developing a range of these multi-hormonal and amylin-based drugs. While some are further along in development and could reach patients in the coming years, others are in earlier stages, suggesting a continued evolution of obesity management therapies.